Search results
Results from the WOW.Com Content Network
Anchiano Therapeutics Ltd. Sponsored ADR (ANCN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in ...
Israel had more companies listed in 2012 on the NASDAQ stock exchange than any country outside of the United States and China. [1] [2] As of 2011, some sixty Israeli companies are listed on the Nasdaq. [3] 2000 was the year that saw the most new Israeli listings on the exchange – 33 companies. [4]
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 23.) Applied Therapeutics Inc (NASDAQ ...
Yahoo Finance is a media property that is part of the Yahoo network. It provides financial news, data and commentary including stock quotes, press releases, financial reports, and original content. It also offers some online tools for personal finance management.
This led to the founding in 1997 of APP Pharmaceuticals, of which he held 80% of the outstanding stock and sold to Fresenius SE for $4.6 billion in July 2008. [36] Soon-Shiong later founded Abraxis BioScience (maker of the drug, Abraxane), [ 5 ] a company he sold to Celgene in 2010 in a cash-and-stock deal valued at just $2.9 billion, earning ...
Yahoo Finance 9 hours ago Google stock pops as company unveils new quantum computing chip. Google said that a math equation that would take a classical supercomputer longer than the whole history ...
Stan Polovets was born in 1963 in Moscow, USSR.His family immigrated to the United States in 1976, and he became a naturalized U.S. citizen in 1983. [12] He received a Bachelor of Science degree from California State University, Northridge (1985), and attended Stanford University, graduating with an MBA and MA in 1989.
The firm was established in 2003 as a joint venture of Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors. [3] It executed an initial public offering on the Tel Aviv Stock Exchange in February 2007, raising 211 million NIS ($50 million) – the TASE's largest biotech IPO until that time.